NCT00098332 - Forodesine (BCX-1777) in Treating Patients With Refractory Stage IIA, Stage IIB, Stage III, Stage IVA, or Stage IVB Cutaneous T-Cell Lymphoma | Biotech Hunter

Timeline

Start Date

November 30, 2004

Primary Completion Date

December 31, 2010

Study Completion Date

July 31, 2011

Conditions

Lymphoma

Interventions

DRUG

forodesine hydrochloride

Trial Locations (10)

Duke Comprehensive Cancer Center, Durham

Cancer and Blood Disease Center, Lecanto

Lurleen Wallace Comprehensive Cancer at University of Alabama-Birmingham, Birmingham

Charles M. Barrett Cancer Center at University Hospital, Cincinnati

Burke Pharmaceutical Research, Hot Springs

University of Colorado Cancer Center at UC Health Sciences Center, Aurora

Stanford Comprehensive Cancer Center - Stanford, Stanford

Yale Cancer Center, New Haven

Dana-Farber/Brigham and Women's Cancer Center, Boston

M.D. Anderson Cancer Center at University of Texas, Houston